Acute kidney injury (AKI) is a global health challenge of vast proportions, as approx. 13.3%
of people worldwide are affected annually. The pathophysiology of AKI is very complex, but …

Onconephrology is a new subspecialty of nephrology that recognizes the important
intersections of kidney disease with cancer. This intersection takes many forms and includes …

Immune checkpoint inhibitors (ICIs) are the standard of care for the treatment of several
cancers. While these immunotherapies have improved patient outcomes in many clinical …

Background Immune checkpoint inhibitor-associated acute kidney injury (ICPi-AKI) has
emerged as an important toxicity among patients with cancer. Methods We collected data on …

Immune checkpoint inhibitors (ICIs) are widely used for various malignancies. However,
their safety and efficacy in patients with a kidney transplant have not been defined. To …

Introduction Immune checkpoint inhibitors (ICIs) are increasingly used to treat cancers.
Kidney immune-related adverse events (IRAEs) are now well recognized, with the incidence …

Introduction Little evidence exists on the safety and efficacy of the rechallenge of immune
checkpoint inhibitors (ICIs) after immune-related adverse events (irAEs) in patients with …

Abstract Background/objectives Acute Kidney Injury (AKI), induced by Checkpoint Inhibitors
therapies (CPI-induced AKI), is an uncommon but severe Immune-Related Adverse Event …

Introduction Immune checkpoint inhibitors (ICIs) are effective in treating several cancers;
however, acute kidney injury (AKI) can occur as part as an immune-related adverse event …

The association between chronic kidney disease (CKD) and renal cell carcinoma (RCC) is
bidirectional and multifactorial. Risk factors such as hypertension, diabetes mellitus, obesity …